Rosiglitazone attenuates atrial structural remodeling and atrial fibrillation promotion in alloxan-induced diabetic rabbits

Cardiovascular Therapeutics

Volumn 32, Issue 4, 2014, Pages 178-183

  Liu, Tong ^a   Zhao, Hui ^b   Li, Jian ^a   Korantzopoulos, Panagiotis ^c   Li, Guangping ^a  

^a SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN HOSPITAL   (China)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Atrial fibrillation; Atrial remodeling; Diabetes; Inflammation; Oxidative stress; Rosiglitazone

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; INSULIN; MALONALDEHYDE; ROSIGLITAZONE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ALLOXAN; ANTIDIABETIC AGENT; AUTACOID; BIOLOGICAL MARKER;

ALLOXAN-INDUCED DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATRIAL INTERSTITIAL FIBROSIS; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFECT; ENZYME ACTIVITY; EXPERIMENTAL RABBIT; FIBROSING ALVEOLITIS; GLUCOSE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HEART ATRIUM REMODELING; HISTOLOGY; INSULIN BLOOD LEVEL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TIME; ANIMAL; ATRIAL FIBRILLATION; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; FIBROSIS; HEART ATRIUM; HEART ATRIUM FUNCTION; HEART PACING; PATHOLOGY; PATHOPHYSIOLOGY; RABBIT;

ALLOXAN; ANIMALS; ATRIAL FIBRILLATION; ATRIAL FUNCTION, LEFT; ATRIAL REMODELING; BIOLOGICAL MARKERS; CARDIAC PACING, ARTIFICIAL; DIABETES MELLITUS, EXPERIMENTAL; FIBROSIS; HEART ATRIA; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; OXIDATIVE STRESS; RABBITS; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 84903946876     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12079     Document Type: Article

References (26)

1. Lip GY, Tse HF, Lane DA. Atrial fibrillation. Lancet 2012;379:648-661.
2. Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol 2005;105:315-318.
3. Lip GY, Varughese GI. Diabetes mellitus and atrial fibrillation: Perspectives on epidemiological and pathophysiological links. Int J Cardiol 2005;105:319-321.
4. Liu C, Fu H, Li J, et al. Hyperglycemia aggravates atrial interstitial fibrosis, ionic remodeling and vulnerability to atrial fibrillation in diabetic rabbits. Anadolu Kardiyol Derg 2012;12:543-550.
5. Fu H, Liu C, Li J, et al. Impaired atrial electromechanical function and atrial fibrillation promotion in alloxan-induced diabetic rabbits. Cardiol J 2013;20:59-67.
6. Liu T, Li G. Inflammation: Another potential mechanism between diabetes mellitus and atrial fibrillation. Am J Cardiol 2008;101:1681-1682.
7. Liu T, Korantzopoulos P, Li G, Li J. The potential role of thiazolidinediones in atrial fibrillation. Int J Cardiol 2008a;128:129-130.
8. Korantzopoulos P, Kokkoris S, Kountouris E, Protopsaltis I, Siogas K, Melidonis A. Regression of paroxysmal atrial fibrillation associated with thiazolidinedione therapy. Int J Cardiol 2008;125:e51-e53.
9. Liu T, Li G. Thiazolidinediones as novel upstream therapy for atrial fibrillation in diabetic patients: A review of current evidence. Int J Cardiol 2012;156:215-216.
10. Liu C, Liu T, Li G. Pioglitazone may offer therapeutic advantages in diabetes-related atrial fibrillation. Int J Cardiol 2013a;168:1603-1605.
11. Duzguner V, Kaya S. Effect of zinc on the lipid peroxidation and the antioxidant defense systems of the alloxan-induced diabetic rabbits. Free Radic Biol Med 2007;42:1481-1486.
12. Misra HP, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972;247:3170-3175.
13. Kato T, Yamashita T, Sekiguchi A, et al. Ages-rage system mediates atrial structural remodeling in the diabetic rat. J Cardiovasc Electrophysiol 2008;19:415-420.
14. Stadler K. Oxidative stress in diabetes. Adv Exp Med Biol 2012;771:272-287.
15. Liu T, Li G, Li L, Korantzopoulos P. Association between c-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: A meta-analysis. J Am Coll Cardiol 2007;49:1642-1648.
16. Liu T, Li L, Korantzopoulos P, Goudevenos JA, Li G. Meta-analysis of association between c-reactive protein and immediate success of electrical cardioversion in persistent atrial fibrillation. Am J Cardiol 2008b;101:1749-1752.
17. Rudolph V, Andrie RP, Rudolph TK, et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med 2010;16:470-474.
18. Korantzopoulos P, Kolettis TM, Galaris D, Goudevenos JA. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol 2007;115:135-143.
19. Liu C, Liu T, Li G. Pioglitazone may offer therapeutic advantages in diabetes-related atrial fibrillation. Int J Cardiol 2013b;168:1603-1605.
20. Shimano M, Tsuji Y, Inden Y, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. Heart Rhythm 2008;5:451-459.
21. Kume O, Takahashi N, Wakisaka O, et al. Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. Heart Rhythm 2011;8:278-285.
22. Xu D, Murakoshi N, Igarashi M, et al. Ppar-gamma activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model. J Cardiovasc Electrophysiol 2012;23:209-217.
23. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (record): A multicentre, randomised, open-label trial. Lancet 2009;373:2125-2135.
24. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study (prospective pioglitazone clinical trial in macrovascular events): A randomised controlled trial. Lancet 2005;366:1279-1289.
25. Chao TF, Leu HB, Huang CC, et al. Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes. Int J Cardiol 2012;156:199-202.
26. Gu J, Liu X, Wang X, et al. Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus. Europace 2011;13:1256-1261.